Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
about
Antigen-specific active immunotherapy for ovarian cancerHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyChemoresistance and targeted therapies in ovarian and endometrial cancersMinireview: Regulatory T Cells and Ovarian Cancer.The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancerOvercoming immunosuppression to enhance a p53MVA vaccine.Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune responseUsing MRI to evaluate and predict therapeutic success from depot-based cancer vaccines.Trial watch: Peptide vaccines in cancer therapyA phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.Immunotherapy in ovarian cancer.Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy.The changing landscape of therapeutic strategies for recurrent ovarian cancer.Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Therapeutic vaccines for cancer: an overview of clinical trials.Brain Tumor Immunotherapy: What have We Learned so Far?The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Vaccines for established cancer: overcoming the challenges posed by immune evasion.The importance of correctly timing cancer immunotherapy.Home sweet home: the tumor microenvironment as a haven for regulatory T cells.Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.T cell modulation by cyclophosphamide for tumour therapy.Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.Cancer Vaccines in Ovarian Cancer: How Can We Improve?
P2860
Q24193567-CC807079-C566-4E62-8A4D-E51F845C4D15Q27021570-0D9F18E9-EECC-44C9-8D24-EF9BECACA303Q28073246-3CB2B353-F633-4090-9790-5186C45F8B70Q30244214-CA1287C3-D635-4A60-BA80-55AC28227E0FQ33736218-E92964A7-277A-4927-A0B2-51BECCD2F870Q33738937-EE243125-57C3-486B-98A9-0038F8E73419Q34934247-87F75CA0-575A-4E3E-8F2E-52A1FCDCCA66Q35201890-B780E706-ADA6-4E2A-967F-E3DF9B8C4B9CQ36388915-BB9B0DD7-6C94-438F-980C-09341AAB02E6Q36476100-79853EFB-7F04-440B-8F0D-83C54DBEC3A9Q36544827-1DF5B1EF-429F-45FC-9953-F2BC45115C3FQ36631249-C9250430-AAC2-4E2D-BDC6-FAA95468FA9EQ36791766-55D8CD1B-8D6D-48D5-9CBE-8C23BFD82A55Q38036688-D3A3B4B3-1316-4519-BB37-69038569B569Q38048887-C22D33B1-E44B-448A-88AA-E188320372C1Q38110540-4C998D46-95AB-43C6-BF66-F5D73B42B827Q38168904-E3E663DD-AC3A-4DBA-961E-B55C1C5A0992Q38227030-E44CD119-4AA8-4674-879F-5A6CFB185CB7Q38542113-70BDBC2E-E4C8-44F1-91D7-B67FA90057AAQ38715211-E06FC6A1-33E2-47E4-9B89-34BA6F9DAC25Q38769021-31751C9C-8979-4022-AB66-3DDC8EB51C6FQ38995979-C9498EE5-1B78-43AC-9927-908A1BABC8A6Q43090164-264E465A-6B01-4B08-897F-CE9A75D59865Q47194123-685CF94B-3AB7-4A94-AB2F-D00A52501113Q47561666-6AD71E88-E7FE-4C55-B97E-460FDF9D0AA2Q49822317-020DDBA7-C953-451E-B8BB-A97C241A180BQ53009456-391EE5E8-1A72-407E-9FC1-A6DEB4A2F291Q54385315-0A16C508-44DB-44DE-978B-C8790D7D814C
P2860
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Potentiation of a p53-SLP vacc ...... : a single-arm phase II study.
@en
Potentiation of a p53-SLP vacc ...... : a single-arm phase II study.
@nl
type
label
Potentiation of a p53-SLP vacc ...... : a single-arm phase II study.
@en
Potentiation of a p53-SLP vacc ...... : a single-arm phase II study.
@nl
prefLabel
Potentiation of a p53-SLP vacc ...... : a single-arm phase II study.
@en
Potentiation of a p53-SLP vacc ...... : a single-arm phase II study.
@nl
P2093
P2860
P356
P1476
Potentiation of a p53-SLP vacc ...... : a single-arm phase II study.
@en
P2093
Anna K L Reyners
Ate G J van der Zee
Barbara H W Molmans
Baukje-Nynke Hoogeboom
Cornelis J Melief
Hans W Nijman
Harry Hollema
Ineke L E Hamming
Jaap Oostendorp
Jan W Drijfhout
P2860
P304
P356
10.1002/IJC.27388
P577
2012-01-31T00:00:00Z